At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
SHR-1210drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Classic Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating SHR-1210 for Hodgkin Lymphoma, Adult. Completed, enrolled 75 participants across 2 sites.
Detailed Summary
This is an open-label, multicenter, non-randomized, phase 2 trial to evaluate efficacy and safety of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma. The primary objective is to assess ORR of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma, Adult
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJun 2017
Primary CompletionAug 2020
Study CompletionSep 2020
TodayJul 2026
First PostedMay 16, 2017
Enrollment StartJun 9, 2017
Primary CompletionAug 31, 2020
Study CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.1 years ago
Interventions
SHR-1210drug
A humanized monoclonal immunoglobulin